Low-dose naltrexone: a familiar drug at a fraction of the dose, doing something else

The same molecule approved at 50 mg for opioid and alcohol dependence, used at 1.5 to 4.5 mg for something entirely different. The dose is not a smaller version of the same intervention — it is the whole basis for the claim.

Why the low dose is the point

Established clinical use At its approved dose naltrexone blocks opioid receptors continuously, which is what makes it useful in dependence. Animal-only or theoretical The low-dose proposal is different: a brief, partial blockade taken at night is said to provoke a compensatory upregulation of endogenous opioid production and receptor expression once the drug clears — a rebound rather than a block. A second and increasingly emphasised mechanism is antagonism at toll-like receptor 4 on microglia and other immune cells, which is where the anti-inflammatory and neuroinflammation claims come from and which is not an opioid mechanism at all.

Both are plausible and neither is settled in humans. The TLR4 account has better mechanistic support; the endorphin-rebound account is the older story and is the one most often repeated. The app models a half-life around six hours, which is consistent with a bedtime dose producing transient exposure and being gone by morning — the schedule is doing real work in the hypothesis rather than being a convenience.

What the evidence actually covers

Off-label or community practice Small randomised trials have reported benefit in fibromyalgia and in Crohn’s disease, and there is a wider body of observational and open-label work across multiple sclerosis, complex regional pain syndrome and other chronic pain and autoimmune conditions. The trials are genuinely randomised and genuinely small — tens of participants rather than hundreds — and large confirmatory trials have not been run. That is an unusual evidence profile: better than most things on this site, considerably weaker than an approved indication.

The practical consequences are two. Effects are described as taking four to eight weeks rather than days, so an early judgement is premature. And there is no biomarker that tracks it: the app records inflammatory markers where they are relevant to the underlying condition, but nothing on the panel tells you whether the drug is doing what it is supposed to. Assessment is symptomatic, which makes a written record of how you actually felt over time more useful here than almost anywhere else in this reference.

The interaction that is not negotiable

Naltrexone is an opioid antagonist at any dose. Taken alongside opioid analgesics it blunts or blocks them, and in someone who is opioid-dependent it can precipitate withdrawal. This is why the standard guidance is a gap of hours around any opioid dose and why anyone facing planned surgery needs the prescriber to know they are taking it — not because low-dose naltrexone is dangerous, but because analgesia planned without that knowledge may not work.

The other practical constraint is supply: 1.5 to 4.5 mg is not a manufactured strength, so it comes from a compounding pharmacy, and the accuracy of a compounded low-dose capsule is the compounder’s to guarantee. This site names no pharmacy.

Vivid dreams and disturbed sleep in the first weeks are the commonly reported effects and usually settle. Anything that does not, or anything on the list below, belongs with the clinician who prescribed it — particularly for anyone with liver disease, where the drug’s metabolism becomes a real consideration rather than a theoretical one.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Established clinical use Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Low-Dose Naltrexone, verbatim. None of the analytes it names has a page here yet.

Drawbacks and risks the app records

From the app’s own entry, and the opioid item is the one with immediate practical consequences rather than gradual ones.

• Vivid dreams initially — usually temporary
• Should not be taken within 4-6 hours of opioid pain medications
• Requires compounding pharmacy for low-dose formulations
• Limited large RCT data despite promising smaller studies
• Not FDA approved at low doses
• Takes 4-8 weeks for full effect

Interaction rules that name Low-Dose Naltrexone

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

Why at bedtime?

Because the endorphin-rebound hypothesis depends on transient exposure — a brief blockade overnight with the drug cleared by morning. Whether that mechanism is the operative one is unsettled, but the schedule follows from it and is what the trials used.

How long before it is worth judging?

The reported window is four to eight weeks. That is longer than most people expect, and it is the main reason people conclude it did nothing.

Can it be taken with painkillers?

Not with opioid ones without a prescriber’s plan — it antagonises them and can precipitate withdrawal in someone dependent. Non-opioid analgesics are unaffected. Anyone scheduling surgery should raise it in advance.

Is there a blood test that shows it is working?

No. Inflammatory markers are followed where the underlying condition warrants it, but nothing on a panel tracks the drug itself. Assessment is symptomatic, over weeks.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.